Skip to main content
Lontrue Co.,Limited logo

Lontrue Co.,Limited — Investor Relations & Filings

Ticker · 300175 ISIN · CNE1000010W0 LEI · 655600YYTHWHAOS3BR55 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,503 across all filing types
Latest filing 2018-09-11 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300175

About Lontrue Co.,Limited

https://www.lontrue.com

Lontrue Co., Limited specializes in the processing, distribution, and international export of agricultural commodities. The company's primary product portfolio includes a wide range of oilseeds and nuts, specifically focusing on peanuts, sunflower seeds, and pumpkin seeds. Additionally, the firm manages the processing of dried fruits and other specialty agricultural goods. Lontrue operates extensive processing facilities equipped with advanced sorting and grading technologies to ensure compliance with international food safety standards, such as HACCP and ISO certifications. By maintaining an integrated supply chain, the company facilitates large-scale trade operations across global markets, including Europe, Southeast Asia, and the Middle East. Its business model emphasizes quality control, consistent supply, and the provision of raw materials for the global food manufacturing and snack industries.

Recent filings

Filing Released Lang Actions
关于签订《上海东方杰玛基因生物科技有限公司增资协议之补充协议》暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a supplemental agreement to an investment capital increase agreement involving a related party transaction. It details the transaction background, parties involved, approval procedures, and the terms of the supplemental agreement, including the establishment of a joint account and equity compensation clauses if performance targets are not met. The document also includes opinions from the supervisory board and independent directors, and it states that the transaction will be submitted to the shareholders' meeting for approval. There are no financial statements or comprehensive financial data presented; rather, it is a disclosure of a corporate transaction and related governance matters. This fits the category of a Capital/Financing Update (CAP) as it concerns investment capital increase and related agreements. The document length (5800 characters) and content confirm it is not a full financial report or an announcement of a report publication but a substantive announcement of a financing transaction and related corporate governance disclosures.
2018-09-11 Chinese
第三届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Langyuan Co., Ltd. It details the approval of a related-party transaction involving an investment agreement and the decision to convene an extraordinary general meeting. The text includes voting results and references to further information on a regulatory disclosure website. The document is short (1164 characters) and serves as a public notice of board decisions rather than a full report or detailed financial disclosure. It does not contain financial statements, management discussion, or audit information. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2018-09-11 Chinese
关于对深圳证券交易所关注函回复的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company (朗源股份有限公司) responding to a regulatory inquiry (关注函) from the Shenzhen Stock Exchange. It discusses specifics about a share transfer, capital increase agreements, performance commitments, financial data, and valuation details related to an investment in another company (东方杰玛). The content includes detailed financial forecasts, audit references, and contractual terms related to the capital increase and shareholding. This is not a full annual or interim report but a regulatory response with substantive financial and contractual information. It is not a simple announcement of a report publication, nor is it a certification or insider dealing report. The document is a regulatory filing responding to an exchange's inquiry, providing detailed explanations and data to comply with regulatory requirements. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2018-09-11 Chinese
独立董事关于第三届董事会第二十三次会议相关事项的事前认可和独立意见
Board/Management Information Classification · 95% confidence The document is titled as an independent directors' pre-approval and independent opinion regarding matters of the 23rd meeting of the third board of directors. It discusses the review and approval of a related-party transaction involving a capital increase agreement supplement. The content focuses on governance and compliance with listing rules and company articles, with independent directors providing their opinions and approval for the transaction to be submitted to the board and shareholders. There are no financial statements, earnings data, or report attachments. The document is a governance-related statement by independent directors on board matters, not a full report or announcement of financial results. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board opinions and approvals, not a report publication or regulatory filing. Confidence is high due to clear governance context and independent directors' opinions on board meeting matters.
2018-09-11 Chinese
关于延期回复深圳证券交易所关注函的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding a delay in responding to a regulatory inquiry (关注函) from the Shenzhen Stock Exchange. It discusses the reasons for the delay, the company's efforts to prepare the response, and the expected new deadline for the reply. The document does not contain financial statements, audit results, or detailed financial data. It is a regulatory communication about compliance and information disclosure obligations rather than a financial report or detailed management discussion. The document length is short (1835 characters), and it serves as an official announcement about the status of a regulatory response. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-09-04 Chinese
上海东方杰玛基因生物科技有限公司因增资扩股涉及的股东全部权益价值评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an "股东全部权益价值评估报告" which translates to "Shareholders' Equity Valuation Report" related to capital increase and share expansion. It is issued by an asset valuation company and contains detailed valuation methods, asset and liability breakdowns, company background, and financial data as of December 31, 2017. The purpose is to assess the total equity value of shareholders for the capital increase. This is a standalone asset valuation report, not a full annual or interim financial report, nor an announcement or certification. It is a specialized audit/valuation report related to the company's equity value for financing purposes. Therefore, it fits best under Audit Report / Information (AR) category, which includes standalone audit and valuation reports excluding full annual reports. The document length is substantial and contains detailed financial and valuation data, confirming it is a full report, not just an announcement or certification. FY 2017
2018-08-28 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.